Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757782 | 0.93 | GPR119 (0.43) | GPR119CYP4F2CYP4A11HPGDSDRD2 | |
| SCHEMBL16757990 | 0.92 | CYP4F2 (0.42) | GPR119CYP4F2CYP4A11HPGDSDRD2 | |
| SCHEMBL16757862 | 0.92 | GPR119 (0.43) | GPR119CYP4F2CYP4A11HPGDSDRD2 | |
| SCHEMBL15539786 | 0.91 | GPR119 (0.43) | GPR119CYP4F2CYP4A11HPGDS | |
| SCHEMBL15538998 | 0.89 | GRM2 (0.42) | DRD2DRD4GRM2 | |
| SCHEMBL16757789 | 0.89 | GPR119 (0.46) | GPR119CYP4F2CYP4A11DRD2DRD4 | |
| SCHEMBL20053594 | 0.88 | GPR119 (0.46) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL15538429 | 0.88 | GPR119 (0.41) | GPR119HPGDSGRM2 | |
| SCHEMBL15539452 | 0.88 | SSTR5 (0.43) | DRD2DRD4GRM2 | |
| SCHEMBL15539170 | 0.87 | GPR119 (0.55) | GPR119CYP4F2CYP4A11HPGDSDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | GPR119 1/4885CYP4F2 2315/4885CYP4A11 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.